Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Elucidate the link between combinations of mutations and disease heterogeneity of high grade serous ovarian cancer

FY 2019-20

Summary
"High grade serous ovarian cancers (HGSCs) is the fifth largest cause of cancer-related death in women. The mechanisms of the early disease progression are still largely unknown due to late diagnosis at the advanced stages in most patients and lack of animal models. Since HGSCs are driven by copy number alterations, identifying a gene(s) important for tumorigenesis in each deleted locus has been challenging. In addition, the cell-of-origin of HGSCs is debated between the fallopian tube (FT) and the ovarian surface epithelium (OSE). To address these challenges, we have developed a novel strategy to derive HGSCs in mice with CRISPR-mediated genome modification and in vivo FT/OSE electroporation. This strategy possesses the advantages of testing various mutation combinations in a limited region. Our previous study revealed that the combinations of gene mutations control cell-of-origin, latency and pathophysiology of HGSC. To elucidate such variation, I hypothesize that there is a link between mutation combinations and heterogeneity of HGSCs. To test this, we aim to perform a survival experiment with two, three and four genes mutation combinations targeting either FTE or OSE. The survival of mice and the genotypes of developed HGSCs will be monitored to investigate the effect of mutation combinations on tumour aggressiveness. To evaluate the effect on HGSC initiation and progression, we will also study the expression profile and related molecular pathways in the precancerous lesions, primary HGSCs and metastasis tumor from each cohort. Understanding the relationship between mutational profiles and HGSCs' pathophysiology can provide an insight into the origin of HGSCs, the fundamental pathways in tumour development, which could serve as future therapeutically targets. "
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
428944
Name
Li YuQi
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Elucidate the link between combinations of mutations and disease heterogeneity of high grade serous ovarian cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Combination Of Tumor Suppressor Gene Mutation; Crispr-Cas9; Electroporation; Fallopian Tube Epithelium; Heterogeneity; High Grade Serous Ovarian Cancer; Metastasis; Mice Model; Ovarian Surface Epithelium; Tumor Development And Progression
Abstract
"High grade serous ovarian cancers (HGSCs) is the fifth largest cause of cancer-related death in women. The mechanisms of the early disease progression are still largely unknown due to late diagnosis at the advanced stages in most patients and lack of animal models. Since HGSCs are driven by copy number alterations, identifying a gene(s) important for tumorigenesis in each deleted locus has been challenging. In addition, the cell-of-origin of HGSCs is debated between the fallopian tube (FT) and the ovarian surface epithelium (OSE). To address these challenges, we have developed a novel strategy to derive HGSCs in mice with CRISPR-mediated genome modification and in vivo FT/OSE electroporation. This strategy possesses the advantages of testing various mutation combinations in a limited region. Our previous study revealed that the combinations of gene mutations control cell-of-origin, latency and pathophysiology of HGSC. To elucidate such variation, I hypothesize that there is a link between mutation combinations and heterogeneity of HGSCs. To test this, we aim to perform a survival experiment with two, three and four genes mutation combinations targeting either FTE or OSE. The survival of mice and the genotypes of developed HGSCs will be monitored to investigate the effect of mutation combinations on tumour aggressiveness. To evaluate the effect on HGSC initiation and progression, we will also study the expression profile and related molecular pathways in the precancerous lesions, primary HGSCs and metastasis tumor from each cohort. Understanding the relationship between mutational profiles and HGSCs' pathophysiology can provide an insight into the origin of HGSCs, the fundamental pathways in tumour development, which could serve as future therapeutically targets. "
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, YuQi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~